HC Wainwright keeps "buy" on ORIC Pharmaceuticals but cuts price target to $20 from $27
HC Wainwright & Co. maintained its "buy" rating on ORIC Pharmaceuticals and cut its price target to $20 from $27, a 25.9% reduction. The new target implies 161.4% upside from the November 18 close of $7.65. The five most recent analyst notes on the company over the past 30 days set price targets between $14 and $26.
In 25 seconds
- HC Wainwright maintains its "buy" rating on ORIC Pharmaceuticals.
- The price target drops to $20 from $27, a 25.9% cut.
- The new target implies 161.4% upside from the November 18 close of $7.65.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.





Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.